1 paper1 finding
Cardiovascular combination therapy
downin humans1
Cardiovascular combination therapy decreases Alzheimer's disease neuropathology in humans (estimate=-0.22; p<0.01).
“therapies with three medication classes were associated with lower odds of atherosclerosis (OR=0.47;p<0.01) and arteriolosclerosis (OR=0.53;p=0.01), but higher odds of brain infarcts (OR=1.74;p=0.01), particularly macroinfarcts (OR=1.66;p=0.03), as well as with less global AD pathology (estimate=‐0.22; p <0.01)”
Humansbrain
Association of combination cardiovascular therapies with cognitive decline and neuropathologies
AAIC 2025 abstract23 Dec 2025
National Institute on AgingUS$3.1m
Brain donors with early-life farming exposure had 60% higher odds of Alzheimer's disease neuropathology than those without such exposure.Brain donors with early-life farming exposure had 60% higher odds of Alzheimer's disease neuropathology than those without such exposure.
A two-year randomised trial in 1,260 older adults at risk of dementia found no clear evidence that starting blood markers altered cognitive benefits.A two-year randomised trial in 1,260 older adults at risk of dementia found no clear evidence that starting blood markers altered cognitive benefits.
In an autopsy cohort of 2,592 older adults, higher education was linked to lower amyloid and tau pathology in female participants but not in males.In an autopsy cohort of 2,592 older adults, higher education was linked to lower amyloid and tau pathology in female participants but not in males.